Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study

Yubero, A; Barquin, A; Estevez, P; Pajares, B; Sanchez, L; Reche, P; Alarcon, J; Calzas, J; Gaba, L; Fuentes, J; Santaballa, A; Salvador, C; Manso, L; Herrero, A; Taus, A; Marquez, R; Madani, J; Merino, M; Marquina, G; Casado, V; Constenla, M; Gutierrez, M; Dosil, A; Gonzalez-Martin, A

Yubero, A (通讯作者)，Hosp Clin Univ Lozano Blesa, Med Oncol, Zaragoza, Spain.

BMC CANCER, 2022; 22 (1):

Abstract

Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ova......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索